Backs FY25 revenue view flat to up 3%. The company said, “While reported and organic net sales growth are expected to be towards the lower end of their respective ranges, due primarily to infant formula industry dynamics and market consumption trends, the Company reaffirms all of its full-year 2025 financial targets.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRGO:
- PRGO Upcoming Earnings Report: What to Expect?
- Perrigo’s Strategic Divestiture: Strengthening Core Operations and Enhancing Shareholder Value
- Perrigo Sells Dermacosmetics Business for €327 Million
- Perrigo to sell Dermacosmetics business for up to EUR 327M
- Perrigo Company’s Strategic Enhancements and FY25 Guidance Reinforce Buy Rating